This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
TRAM1 / Translocating chain-associated membrane protein 1 · IHC design guide
Design Immunohistochemistry for TRAM1
Plan chromogenic TRAM1 IHC in paraffin sections with the catalog antibody at 0.5–1 μg/ml (datasheet: PA2010). Assess variable cytoplasmic and nuclear tissue staining (HPA tissue IHC) against the expected ER membrane location (UniProt).
Evidence assembled Oct 2026 · For research use; verify linked source records and product datasheet before use
TRAM1 Immunohistochemistry Experimental Design Guide
Expected localisation, validated protocols, controls and antibodies — the at-a-glance facts below, then the full design guide.
Must know before staining
| Expected localisation | ER membrane expected (UniProt); cytoplasmic and nuclear staining observed (HPA tissue IHC) | |
| Staining pattern | Variable cytoplasmic and nuclear staining across tissues (HPA tissue IHC) | |
| Antigen retrieval | Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen) | |
| Positive control | Cervix+4 more · see all | |
| Negative control | Fallopian tube+1 more · see all |
Important caveats
Reasons your staining may differ from the expected pattern.
| Fixation | Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image PA2010) | |
| Caveat | Low consistency between antibody staining and RNA expression (HPA tissue IHC) | |
| Regulation | Expression regulation is not annotated (UniProt) | |
| Isoform / epitope | 2 isoforms; check epitope coverage and cytoplasmic versus luminal location (UniProt) |
Section 1
Recommended TRAM1 IHC & IF Protocols
Compare the catalog antibody’s IHC-P protocol with the published TRAM1 IHC protocol for pancreatic tumor and matched normal tissue microarrays (PMC4718295 methods).
| Sample | Tissue sections; selected-image fixative not specified (standard IHC workflow) |
| Fixation | Image fixative and duration unreported (datasheet PA2010); verify before use. |
| Sectioning | 4–5 µm sections on charged slides (standard) |
| Deparaffinisation | Xylene, graded ethanol series to water (standard) |
| Antigen retrieval | Heat-induced epitope retrieval in citrate buffer, pH 6.0, 20 min at 95–98 °C (standard rule: cytoplasmic / membrane antigen) |
| Peroxidase block | 3% H2O2, 10 min, room temperature (standard) |
| Blocking | 10% normal serum of the secondary host, 30 min, room temperature (standard) |
| Primary antibody | Rabbit anti-TRAM1, 0.5-1μg/ml (datasheet PA2010) |
| Primary incubation | Overnight at 4 °C (standard) |
| Detection | HRP-polymer secondary, DAB chromogen 5–10 min (standard) |
| Counterstain | Hematoxylin, blue, dehydrate and mount (standard) |
| Expected result | TRAM1-positive staining in squamous epithelial cells of cervix (HPA tissue IHC: High). HPA tissue profile: Cytoplasmic and nuclear expression at variable levels in all tissues. No signal in the no-primary control. |
💡Decision noteStart with citrate pH 6.0 retrieval at 95–98 °C for 20 min (page retrieval rule); the article does not specify retrieval conditions (PMC4718295 methods).
Section 2
What Is the Expected TRAM1 Staining Pattern?
TRAM1 is an eight-pass endoplasmic reticulum (ER) membrane protein, so an ER-associated cytoplasmic pattern is the most coherent positive result (UniProt Q15629 topology). In paraffin-section IHC, HPA reports high staining in selected squamous epithelial, keratinocyte and intestinal glandular cells, alongside variable cytoplasmic and nuclear staining across tissues (HPA tissue IHC). HPA rates its IHC evidence Approved but notes low consistency with RNA expression (HPA tissue IHC).
| Cytoplasmic staining in colon glandular cells or skin keratinocytes. | Both cell populations are reported High by HPA (HPA tissue IHC). An ER-associated cytoplasmic pattern fits TRAM1's membrane location (UniProt Q15629 topology). Assess the distribution within the relevant cells; HPA's tissue score alone does not confirm that every stained structure is ER. |
| Predominantly nuclear staining, with little cytoplasmic signal. | This is discordant with TRAM1's annotated ER membrane location and warrants an artefact check (UniProt Q15629 topology). HPA also reports variable nuclear expression, so nuclear staining alone cannot be declared false from these sources (HPA tissue IHC). Compare it with cytoplasmic staining and detection controls. |
| Strong staining in a cell population expected to be unstained. | Unexpected staining can reflect cross-reactivity or endogenous detection activity (general IHC practice). For example, HPA reports prostate glandular cells as Not detected (HPA tissue IHC). That designation is an observed result, not proof that every prostate specimen or cell must remain negative. |
| Diffuse colour over cells and tissue without a discernible pattern. | A widespread deposit that obscures cell boundaries limits compartment and intensity calls (general IHC practice). It cannot establish the ER-associated pattern predicted by UniProt (UniProt Q15629 topology). Check staining in a no-primary control before interpreting weak tissue signal (general IHC practice). |
| No detectable staining in a documented high-staining tissue. | A failed run is possible if, for example, colon glandular cells or skin keratinocytes lack signal (HPA tissue IHC; general IHC practice). Review tissue preservation, retrieval and detection controls as general workflow checks; these sources do not establish TRAM1-specific fixation sensitivity or a required retrieval condition. |
💡Expected TRAM1 appearanceCall a result positive when documented high-staining epithelial or glandular cells show clear cytoplasmic signal consistent with ER localisation (HPA tissue IHC; UniProt Q15629 topology); isolated nuclear colour or widespread background needs control review before it is assigned to TRAM1 (HPA tissue IHC; general IHC practice).
| Membrane topology and compartment | TRAM1 has eight membrane-spanning segments and cytoplasmic and lumenal regions (UniProt Q15629 topology). Its precise antibody epitope is not supplied, so topology supports an ER-associated interpretation but cannot specify a retrieval method, staining texture or epitope accessibility in paraffin sections. |
| Tissue and cell selection | HPA reports High staining in colon, duodenal and small-intestinal glandular cells and several squamous epithelial populations, while prostate and fallopian-tube glandular cells are Not detected (HPA tissue IHC). These observations guide comparison tissues; HPA also describes variable expression across tissues (HPA tissue IHC). |
| Strength of IHC evidence | HPA lists antibody HPA023929 as IHC Approved and flags low consistency between staining and RNA data (HPA tissue IHC; HPA antibody validation). This supports a cautious pattern comparison, especially for unusual compartments or cells; the supplied antibody record does not list IHC Enhanced validation. |
| Isoforms and processing | UniProt lists two TRAM1 isoforms and a chain spanning residues 1–374, with no annotated signal peptide or propeptide (UniProt Q15629). The supplied record gives no antibody epitope or isoform-specific IHC result, so a difference in staining cannot be assigned to an isoform or processing event. |
| IF/ICC interpretation | For IF/ICC, should membrane staining alone count as ER localisation? No: HPA summarises the subcellular location as Membrane, gives no main location or ICC-IF image set, and lists no ICC validation for HPA023929 (HPA subcellular; HPA antibody validation). This IHC section therefore cannot establish an IF staining pattern. |
| Situation | Likely cause | Next action |
|---|---|---|
| No signal in colon glandular cells or skin keratinocytes. | Either population is reported High, making an absent signal worth investigating; the HPA score does not identify the failed step (HPA tissue IHC). | Check that tissue morphology, a run control and the detection reagents are satisfactory; review retrieval and antibody conditions against the applicable IHC procedure (general IHC practice). No TRAM1-specific retrieval condition is supplied. |
| Nuclei dominate the stain while cytoplasm is faint. | Nuclear predominance conflicts with ER membrane localisation, although HPA reports variable nuclear staining in tissues (UniProt Q15629 topology; HPA tissue IHC). | Inspect the no-primary control and compare cytoplasmic signal in documented high-staining cells (general IHC practice; HPA tissue IHC). Treat a persistent nuclear-only pattern as unresolved rather than calling it confirmed TRAM1. |
| Strong staining appears in prostate glandular cells. | HPA reports this cell population as Not detected; cross-reactivity or endogenous detection activity are possible explanations (HPA tissue IHC; general IHC practice). | Review morphology and no-primary or detection-only controls, then compare the run with a documented high-staining tissue (general IHC practice; HPA tissue IHC). An unexpected positive needs validation before it is scored as TRAM1. |
| Diffuse deposit obscures cell boundaries. | Non-specific antibody binding or endogenous detection activity can raise background in chromogenic IHC (general IHC practice). The deposit cannot be assigned to TRAM1 from colour alone. | Examine a no-primary control, reassess blocking and detection steps, and compare the distribution with intact tissue morphology (general IHC practice). Interpret compartment staining only after background is controlled. |
| Staining is weak or patchy across the section. | HPA describes variable tissue staining, but patchiness can also reflect uneven IHC processing (HPA tissue IHC; general IHC practice). These sources do not establish a TRAM1-specific fixation effect. | Compare intact regions and a documented high-staining control; review section handling, retrieval and reagent coverage as general IHC checks (HPA tissue IHC; general IHC practice). Do not infer altered TRAM1 expression from one weak area. |
| IF/ICC shows a membrane signal, but its location is unclear. | HPA's ICC-IF summary says Membrane without a main location, images or ICC validation for the listed antibody (HPA subcellular; HPA antibody validation). | Use the separate IF/ICC guide to plan localisation controls (general IF practice). Do not transfer this paraffin-section IHC interpretation into an IF protocol or call the IF signal ER-specific from the supplied HPA summary alone. |
Experiment evidence
IHC & IF images showing TRAM1 staining
PA2010 · IHCAnti-TRAM1 antibody, PA2010, IHC(P) IHC(P): Human Lung Cancer Tissue
PA2010 · IHCAnti-TRAM1 antibody, PA2010, IHC(P) IHC(P): Rat Kidney Tissue
PA2010 · IFAnti-TRAM1 antibody, PA2010, ICC ICC: HELA Cell
HPA · Cerebral cortexHuman Protein Atlas IHC, Cerebral cortex. Source: https://www.proteinatlas.org/ENSG00000067167-TRAM1/tissue/cerebral+cortex#imid_6071376
HPA · ColonHuman Protein Atlas IHC, Colon. Source: https://www.proteinatlas.org/ENSG00000067167-TRAM1/tissue/colon#imid_6071310
HPA · LiverHuman Protein Atlas IHC, Liver. Source: https://www.proteinatlas.org/ENSG00000067167-TRAM1/tissue/liver#imid_6071311
HPA · KidneyHuman Protein Atlas IHC, Kidney. Source: https://www.proteinatlas.org/ENSG00000067167-TRAM1/tissue/kidney#imid_6071320
← swipe / scroll for more images →
Real IHC / IF data behind the staining-pattern expectations in this section.
Sample controls for TRAM1 IHC & IF
🧪Run colon first: glandular cells should stain (HPA: High in colon glandular cells). Use fallopian tube glandular cells as the tissue negative (HPA: Not detected in fallopian tube glandular cells); neighboring stromal cells on the colon slide should show only background staining, although HPA does not establish them as TRAM1-negative.
Positive control tissue: Cervix (Squamous epithelial cells, HPA High)
Negative control tissue: Fallopian tube (HPA Not detected)
ICC-IF cell lines (HPA subcellular resource): HPA carries no ICC-IF cell line for TRAM1; derive a cell-line control from the positive tissue's cell type (Squamous epithelial cells) and confirm it by RNA or western blot first.
Technical controls: Include a no-primary (secondary-only) slide, an isotype control matched to the primary antibody’s host species and clonality, and TRAM1 knockout tissue or a peptide-block control if available (standard IHC practice). Block endogenous peroxidase for chromogenic detection and check whether colon luminal material retains nonspecific stain (standard IHC practice).
⚠️Feasibility: No target-specific fixation window or fixation effect is reported in the supplied evidence, and the selected PA2010 tissue-IHC caption does not state a fixative (selected-SKU caption). Antigen-retrieval dependence is unreported; the supplied evidence does not establish whether frozen sections or IF/ICC would be easier. TRAM1 is an ER membrane protein, so evaluate staining against an intracellular ER-like pattern (UniProt Q15629 subcellular location), while checking colon luminal material for nonspecific staining (standard IHC practice).
HPA tissue IHC evidence for TRAM1
Comprehensive Human Protein Atlas IHC scoring per tissue (reliability: Approved — Low consistency between antibody staining and RNA expression data.). Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
Positive expression · recommended positive controls
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Cervix | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Colon | Glandular cells | High | Protein (IHC) | HPA → |
| Duodenum | Glandular cells | High | Protein (IHC) | HPA → |
| Esophagus | Squamous epithelial cells | High | Protein (IHC) | HPA → |
| Oral mucosa | Squamous epithelial cells | High | Protein (IHC) | HPA → |
Section 3
Advanced TRAM1 IHC Tips
Troubleshoot TRAM1 staining in paraffin sections by checking retrieval, compartment, controls, and scoring against its endoplasmic reticulum localisation (UniProt Q15629).
How should I retrieve TRAM1 in paraffin sections when staining is weak?
Use citrate buffer at pH 6.0 for heat induced retrieval at 95–98 °C for 20 minutes (page retrieval specification). Let sections cool in the retrieval buffer before washing, and keep heating and cooling consistent across the staining run (standard IHC practice). If signal remains weak, compare a longer retrieval time or an alternative buffer on adjacent sections, checking simultaneously for tissue damage and increased background (standard IHC practice). Use a strongly staining reference section, such as colon glandular cells, in each comparison; its reported high staining provides a useful benchmark, although antibody staining has low consistency with RNA data (HPA tissue IHC).
Could fixation explain weak or uneven TRAM1 staining?
TRAM1 specific sensitivity to fixation is unknown from the supplied evidence, and the selected PA2010 tissue image does not state a fixative (PA2010 IHC(P) caption). Record the fixative, fixation duration, section thickness, and tissue processing conditions for each specimen before comparing staining intensity (standard IHC practice). Compare affected and reference sections processed together under the same retrieval and detection conditions to isolate a processing difference (standard IHC practice; page retrieval specification). If staining varies within a section, inspect morphology and tissue edges before changing retrieval, since uneven processing can complicate chromogenic staining (standard IHC practice).
Should nuclear or surface staining count as TRAM1 positive?
Prioritise cytoplasmic staining with an endoplasmic reticulum pattern when evaluating TRAM1, an endoplasmic reticulum membrane protein (UniProt Q15629 subcellular location). Its 8 transmembrane segments support a membrane associated intracellular pattern, rather than a distinct cell surface rim (UniProt Q15629 topology). HPA reports variable cytoplasmic and nuclear tissue staining, but also reports low consistency between antibody staining and RNA expression; assess nuclear signal cautiously (HPA tissue IHC). Compare the questioned compartment with reference tissue, morphology, and a negative reagent control before assigning positive cells or interpreting a change in localisation (HPA tissue IHC; standard IHC practice).
How do epitope position and TRAM1 isoforms affect staining?
TRAM1 has 2 reported isoforms and 8 membrane spanning segments, so establish which sequence the antibody recognises before interpreting absent staining (UniProt Q15629 isoforms and topology; standard IHC practice). The supplied evidence does not locate the catalog antibody's epitope or establish recognition of both isoforms; request its immunogen or epitope information when troubleshooting (supplied antibody evidence; standard IHC practice). TRAM1 also has a glycosylation site at residue 56 and a reported phosphoserine at 365, but their effect on this antibody's staining is unknown (UniProt Q15629 PTMs; supplied antibody evidence). Compare sections using the same retrieval and antibody conditions before attributing a difference to an isoform or modification (standard IHC practice).
How can I check a TRAM1 result by multiplex immunofluorescence?
Treat IF as a separate assay requiring validation: the supplied subcellular record lists no ICC/IF images for TRAM1 (HPA subcellular record). Multiplex TRAM1 with a marker for the cell type identified by morphology, and check whether signal falls within the expected cells (standard IF practice; UniProt Q15629 ER location). Choose a fluorophore channel after examining unstained tissue for autofluorescence, and include single stain controls to assess spectral bleed through (standard IF practice). Match permeabilisation to the recognised epitope: TRAM1 has cytoplasmic and lumenal loops, but the antibody's epitope side is unspecified (UniProt Q15629 topology; supplied antibody evidence). Validate fixation and permeabilisation empirically for the IF assay (standard IF practice).
What should I check when chromogenic TRAM1 staining is diffuse or widespread?
First compare the primary antibody section with a matched no primary control to distinguish antibody associated staining from detection background (standard IHC practice). Include a peroxidase blocking step before chromogenic detection and inspect for residual endogenous enzyme signal; this is a general workflow control, not TRAM1 specific evidence (standard IHC practice). Optimise antibody concentration and wash conditions on adjacent sections while retaining the same citrate pH 6.0 retrieval, so the effect of each change remains interpretable (page retrieval specification; standard IHC practice). Widespread cytoplasmic staining alone is insufficient evidence of specificity because HPA reports variable expression across tissues and low antibody versus RNA consistency (HPA tissue IHC).
How should I score TRAM1 staining across paraffin sections? ⚠ ANSWER MARKED FOR VERIFICATION
Define the scored cell population and cytoplasmic compartment before reviewing outcomes, consistent with TRAM1's endoplasmic reticulum location (UniProt Q15629 subcellular location; standard IHC practice). Record the percentage of positive cells and staining intensity, then calculate an H-score on the 0–300 scale if that scoring system suits the study (standard IHC practice). Normalise counts or stained area to the number of evaluable target cells or evaluable tissue area, and apply one threshold to all compared sections (standard IHC practice). Report nuclear staining separately because HPA describes it in tissue IHC while reporting low consistency between staining and RNA expression (HPA tissue IHC).
How can I distinguish genuine TRAM1 signal from staining artefact?
Look for reproducible intracellular cytoplasmic staining in intact cells, consistent with TRAM1's endoplasmic reticulum membrane location (UniProt Q15629 subcellular location; standard IHC practice). Treat an isolated cell surface rim or exclusively nuclear signal as a result needing further validation; HPA reports nuclear staining but notes low consistency with RNA expression (UniProt Q15629 topology; HPA tissue IHC). Exclude tissue edges, necrotic regions, and areas showing signal in the no primary control from interpretation, and check peroxidase blocking if pigment persists (standard IHC practice). Use a reference tissue alongside each run; HPA reports high staining in colon glandular cells, while the PA2010 caption documents staining in human lung cancer tissue without stating its fixative (HPA tissue IHC; PA2010 IHC(P) caption).
Boster reagents
Best TRAM1 / Translocating chain-associated membrane protein 1 IHC Antibodies
PA2010 has IHC images from human and rat tissues and an ICC image from HeLa cells; the catalog lists human, mouse, and rat reactivity (catalog image captions; catalog reactivity).
Real IHC data
Anti-TRAM1 Antibody ®
Cat # PA2010
PA2010 lists IHC, IHC-F, and ICC applications for human, mouse, and rat samples (catalog applications; catalog reactivity). Its images show human lung cancer and rat kidney paraffin sections, rat intestine and brain frozen sections, and HeLa cells in ICC (catalog image captions).
Which to pick: For tissue IHC, choose PA2010: its images show paraffin and frozen sections, but the fixative is unreported (catalog IHC image captions). For IF/ICC, PA2010 lists ICC and has a HeLa ICC image; fluorescent detection is unreported (catalog applications; catalog ICC image caption). For cross-species work, PA2010 lists human, mouse, and rat reactivity; its host is rabbit, and clonality is unreported (catalog reactivity; catalog host; catalog clone).
Each figure is that product's own IHC / IF validation image from its datasheet.
References
- UniProt Consortium. UniProt entry Q15629 (TRAM1_HUMAN, Translocating chain-associated membrane protein 1).
- Human Protein Atlas. TRAM1 tissue IHC expression (reliability: Approved).
- Human Protein Atlas. TRAM1 subcellular location (ICC-IF): Membrane.
- Human Protein Atlas. TRAM1 antibody validation summary (1 antibodies).
- The Immunohistochemical Evaluation of Solid Pseudopapillary Tumors of the Pancreas and Pancreatic Neuroendocrine Tumors Reveals ERO1Lβ as a New Biomarker. Medicine 2016 — PMC4718295.
- PubMed PMID:1315422 — UniProt-cited evidence.
- PubMed PMID:14702039 — UniProt-cited evidence.
- PubMed PMID:16421571 — UniProt-cited evidence.
Immunohistochemistry protocol sheet for TRAM1 (Translocating chain-associated membrane protein 1). Expected localisation ER membrane expected (UniProt); cytoplasmic and nuclear staining observed (HPA tissue IHC). Antigen retrieval: Citrate pH 6.0 HIER, 95–98 °C, 20 min (rule: cytoplasmic / membrane antigen). Validated IHC antibody: PA2010 at 0.5-1μg/ml (the product's own IHC validation image is shown). Controls (HPA): positive Cervix (Squamous epithelial cells); negative Fallopian tube. IHC workflow; specimen preparation unspecified. Protocol steps: 1. Sample: Tissue sections; selected-image fixative not specified (standard IHC workflow); 2. Fixation: Image fixative and duration unreported (datasheet PA2010); verify before use.; 3. Sectioning: 4–5 µm sections on charged slides (standard); 4. Deparaffinisation: Xylene, graded ethanol series to water (standard); 5. Antigen retrieval: Heat-induced epitope retrieval in citrate buffer, pH 6.0 , 20 min at 95–98 °C…; 6. Peroxidase block: 3% H2O2, 10 min , room temperature (standard); 7. Blocking: 10% normal serum of the secondary host, 30 min , room temperature (standard); 8. Primary antibody: Rabbit anti-TRAM1, 0.5-1μg/ml (datasheet PA2010); 9. Primary incubation: Overnight at 4 °C (standard). Watch for: Fixation: Matched tissue-IHC evidence does not establish the fixation claim. Validate the specimen-specific method before use. (selected-SKU IHC image PA2010); Caveat: Low consistency between antibody staining and RNA expression (HPA tissue IHC); Isoform / epitope: 2 isoforms; check epitope coverage and cytoplasmic versus luminal location (UniProt); Regulation: Expression regulation is not annotated (UniProt). Evidence: UniProt Q15629, HPA tissue IHC · Approved, HPA ICC-IF · Membrane, Datasheet PA2010, PMC4718295. QR code links to https://www.bosterbio.com/bosterbio-gene-info-cards/TRAM1/immunohistochemistry-ihc-guide.